Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.77 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.77 |
| ▸ | BCR | P11274 | 7/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
| ▸ | PRKCA | P17252 | 1/20 | 0.77 |
| ▸ | KIT | P10721 | 6/20 | 0.70 |
| ▸ | KDR | P35968 | 2/20 | 0.70 |
| ▸ | ABL2 | P42684 | 1/20 | 0.69 |
| ▸ | BRAF | P15056 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441265 | 1.00 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBEGFR | |
| Hydrochloric Acid SCHEMBL868161 | 0.99 | ABL1 (0.76) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL869136 | 0.97 | ABL1 (0.72) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1415439 | 0.96 | ABL1 (0.74) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL12744294 | 0.96 | ABL1 (0.75) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL5185763 | 0.94 | ABL1 (0.83) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL3533176 | 0.94 | ABL1 (0.75) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1408815 | 0.93 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL1408876 | 0.93 | ABL1 (0.75) | ABL1PDGFRABCRPDGFRBEGFR | |
| SCHEMBL20652847 | 0.93 | ABL1 (0.66) | ABL1PDGFRABCRPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875078-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2021-09-08 | — | — | EP | claimed |
| CN-108495620-B | Pharmaceutical compositions comprising phenylaminopyrimidine derivatives | 纳科制药有限公司 | 2021-09-03 | — | — | CN | claimed |
| EP-3389633-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE | NATCO PHARMA LTD (IN) | 2021-07-14 | — | — | EP | claimed |
| US-10383872-B2 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | NATCO PHARMA LTD (IN) | 2019-08-20 | — | — | US | claimed |
| US-10350209-B2 | — | — | 2019-07-16 | — | — | US | claimed |
| US-20190015412-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE | NATCO PHARMA LTD (IN) | 2019-01-17 | — | — | US | claimed |
| EP-3389633-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE | Natco Pharma Limited (IN) | 2018-10-24 | — | — | EP | claimed |
| CN-108495620-A | Pharmaceutical compositions comprising phenylaminopyrimidine derivatives | 纳科制药有限公司 | 2018-09-04 | — | — | CN | claimed |
| US-9895367-B2 | Formulation comprising phenylaminopyrimidine derivative as active agent | NATCO PHARMA LIMITED (IN) | 2018-02-20 | — | — | US | claimed |
| WO-2017103941-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE | NATCO PHARMA LTD (IN) | 2017-06-22 | — | — | WO | claimed |
| WO-2012120328-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | NATCO PHARMA LIMITED (IN) | 2012-09-13 | — | — | WO | claimed |
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | claimed |
| US-20120077833-A1 | ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2012-03-29 | — | — | US | claimed |
| US-8067422-B2 | Crystal form of phenylamino pyrimidine derivatives | NATCO PHARMA LIMITED (IN) | 2011-11-29 | — | — | US | claimed |
| US-20110190328-A1 | ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | NATCO PHARMA LIMITED (IN) | 2011-08-04 | — | — | US | claimed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | claimed |
| EP-2265599-A2 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVE | Natco Pharma Limited (IN) | 2010-12-29 | — | — | EP | claimed |
| WO-2009109867-A2 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2009-09-11 | — | — | WO | claimed |
| US-20090227611-A1 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | NATCO PHARMA LIMITED (IN) | 2009-09-10 | — | — | US | claimed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383872-B2 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative | NAPRT, NRDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABL1 537/4885PDGFRA 451/4885BCR 443/4885 |
| US-20190015412-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE | NAPRT, NRDC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ABL1 537/4885PDGFRA 451/4885BCR 443/4885 |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | ABL1 1/4885PDGFRA 113/4885BCR 3/4885 |
| US-20110190328-A1 | ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | SLC30A5, DNPEP, PAICS | ABL1 198/4885PDGFRA 8/4885BCR 2506/4885 |
| US-20120077833-A1 | ACID ADDITION SALTS OF (3,5-BIS TRIFLUOROMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3YL-PYRIMIDIN-2YLAMINO)-PHENYL]-BENZAMIDE | CA9, SLC30A5, SLC6A19 | ABL1 157/4885PDGFRA 21/4885BCR 2453/4885 |
| US-20090227611-A1 | CRYSTAL FORM OF PHENYLAMINO PYRIMIDINE DERIVATIVES | WEE1, TP53, CDKN1A | ABL1 386/4885PDGFRA 253/4885BCR 2362/4885 |
| US-10350209-B2 | — | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NR2C2, NR4A1 | ABL1 1953/4885PDGFRA 1417/4885BCR 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.